Neuromuscular Blockade Agents Reversal with Sugammadex Compared to Neostigmine in the Living Kidney Donors

Overview

Journal Open Access Maced J Med Sci

Specialty General Medicine

Date 2020 Mar 28

PMID 32215106

Citations 1

Authors

Thuy Luu Quang

Huyen Nguyen Thi Thu

Kinh Nguyen Quoc

Ha Nguyen Thu

Dong Pham Van

Nguyen Le Bao Tien

Vo Van Thanh

Vu Thi Nga

Chu Dinh Toi

Affiliations

Soon will be listed here.

Abstract

Backround: The reversation of NMBA (neuromuscular blocking agents) prevents numerous postoperative complications, increases quality of recovery and decreases the time, expenditure spending in hospital. The choice of medicine used to reverse NMBA depends considered as a key fators to gain the best outcome and to avoid the side effects.

Aim: To evaluate the postoperative effect on muscle relaxation reversal and side effects of sugammadex 2 mg/kg versus the combination of neostigmine and atropine sulfate in the living kidney donors.

Methods: A randomised controlled trial on 70 patients undergoing living kidney donation surgery were allocated to 2 groups. Patients in group I (SUGA) were reversed with sugammadex 2 mg/kg and in group II (NEO/ATR) with the combination of neostigmine and atropine sulfat.

Results: With 35 patients in each group, the study results showed that after 3 mintutes of reversal patients reaching TOF value ≥ 0.9 in group SUGA is 91.4%, after 5 minutes 100% of patients in group SUGA reached TOF value ≥ 0.9 . In group NEO/ATR after 3 minutes 28.6% patients reached TOF ≥ 0.9 and 40% patients reached TOF≥ 0.9 after 5 minutes. The difference in percentage of patients reaching TOF ≥ 0.9 after 3 minutes, 5 minutes of reversal between two groups is significant (p<0.05). After 10 minutes, 100% patients in both group got TOF ≥ 0.9. Time to exutubation of group SUGA was 249.43 ± 81.75 seconds and it was 456.29 ± 146.45 seconds in group NEO/ATR. Nausea, bradycardia, and increased phlegm production in group NEO/ATR was 22.9%; 28.5%; 25.7% respectively; while those side effects were not met in group SUGA, the difference was significant (p<0.05).

Conclusion: The muscle relaxation reversal effect of sugammadex was faster than that of neostigmine, the duration TOF ≥ 0.9 and the time to extubation was significantly faster. Sugammadex did not cause hemodynamic changes before and after muscle relaxation reversal, neostigmine resulted in the bradycardia, increased phlegm secreting and other side effects. The renal function after 24 hours postoperatively of two groups was similar.

Citing Articles

Sugammadex in awakening from general anesthesia: systematic review and meta-analysis.

Anzai A, Utino A, Tosello G, Katayama H, Spir I, Tristao L Rev Assoc Med Bras (1992). 2022; 68(9):1130-1153.

PMID: 36228244 PMC: 9575014. DOI: 10.1590/1806-9282.2022D687.

References

Reid J, Breslin D, Mirakhur R, Hayes A . Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol. Can J Anaesth. 2001; 48(4):351-5. DOI: 10.1007/BF03014962. View

Bevan J, Collins L, Fowler C, Kahwaji R, Rosen H, Smith M . Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. Anesth Analg. 1999; 89(2):333-9. DOI: 10.1097/00000539-199908000-00016. View

Yazar E, Yilmaz C, Bilgin H, Karasu D, Bayraktar S, Apaydin Y . A Comparision of the Effect of Sugammadex on the Recovery Period and Postoperative Residual Block in Young Elderly and Middle-Aged Elderly Patients. Balkan Med J. 2016; 33(2):181-7. PMC: 4924962. DOI: 10.5152/balkanmedj.2016.16383. View

Hardemark Cedborg A, Sundman E, Boden K, Hedstrom H, Kuylenstierna R, Ekberg O . Pharyngeal function and breathing pattern during partial neuromuscular block in the elderly: effects on airway protection. Anesthesiology. 2013; 120(2):312-25. DOI: 10.1097/ALN.0000000000000043. View

Kopman A, Kopman D, Ng J, Zank L . Antagonism of profound cisatracurium and rocuronium block: the role of objective assessment of neuromuscular function. J Clin Anesth. 2005; 17(1):30-5. DOI: 10.1016/j.jclinane.2004.03.009. View

Sorgenfrei I, Norrild K, Larsen P, Stensballe J, Ostergaard D, Prins M . Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006; 104(4):667-74. DOI: 10.1097/00000542-200604000-00009. View

Donati F . Neuromuscular monitoring: more than meets the eye. Anesthesiology. 2012; 117(5):934-6. DOI: 10.1097/ALN.0b013e31826f9143. View

Carron M, Zarantonello F, Tellaroli P, Ori C . Efficacy and safety of sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-analysis of randomized controlled trials. J Clin Anesth. 2016; 35:1-12. DOI: 10.1016/j.jclinane.2016.06.018. View

Sparr H, Vermeyen K, Beaufort A, Rietbergen H, Proost J, Saldien V . Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007; 106(5):935-43. DOI: 10.1097/01.anes.0000265152.78943.74. View

10.

Blobner M, Eriksson L, Scholz J, Motsch J, Rocca G, Prins M . Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial. Eur J Anaesthesiol. 2010; 27(10):874-81. DOI: 10.1097/EJA.0b013e32833d56b7. View

11.

Bom A, Bradley M, Cameron K, Clark J, van Egmond J, Feilden H . A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002; 41(2):266-70. DOI: 10.1002/1521-3773(20020118)41:2<265::aid-anie265>3.0.co;2-q. View

12.

Wu X, Oerding H, Liu J, Vanacker B, Yao S, Dahl V . Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects. BMC Anesthesiol. 2014; 14:53. PMC: 4153006. DOI: 10.1186/1471-2253-14-53. View

13.

Brueckmann B, Sasaki N, Grobara P, Li M, Woo T, de Bie J . Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015; 115(5):743-51. DOI: 10.1093/bja/aev104. View

14.

Beemer G, Bjorksten A, Dawson P, Dawson R, Heenan P, Robertson B . Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth. 1991; 66(4):469-75. DOI: 10.1093/bja/66.4.469. View

15.

Woo T, Kim K, Shim Y, Kim M, Yoon S, Lim Y . Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients. Korean J Anesthesiol. 2014; 65(6):501-7. PMC: 3888842. DOI: 10.4097/kjae.2013.65.6.501. View

16.

Kim K, Cheong M, Lee H, Lee J . Tactile assessment for the reversibility of rocuronium-induced neuromuscular blockade during propofol or sevoflurane anesthesia. Anesth Analg. 2004; 99(4):1080-1085. DOI: 10.1213/01.ANE.0000130616.57678.80. View

17.

Hristovska A, Duch P, Allingstrup M, Afshari A . Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017; 8:CD012763. PMC: 6483345. DOI: 10.1002/14651858.CD012763. View

18.

Cheong S, Ki S, Lee J, Lee J, Kim M, Hur D . The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. Korean J Anesthesiol. 2015; 68(6):547-55. PMC: 4667139. DOI: 10.4097/kjae.2015.68.6.547. View

19.

Tramer M, Fuchs-Buder T . Omitting antagonism of neuromuscular block: effect on postoperative nausea and vomiting and risk of residual paralysis. A systematic review. Br J Anaesth. 1999; 82(3):379-86. DOI: 10.1093/bja/82.3.379. View

20.

Nag K, Singh D, Shetti A, Kumar H, Sivashanmugam T, Parthasarathy S . Sugammadex: A revolutionary drug in neuromuscular pharmacology. Anesth Essays Res. 2015; 7(3):302-6. PMC: 4173552. DOI: 10.4103/0259-1162.123211. View